Vicente Anido, Aerie CEO (University of West Virginia via YouTube)
Who needs primary endpoints anyway? Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease
Aerie’s dry eye disease drug may not have met the primary endpoints it’s chosen for a Phase IIb study, but that’s not stopping the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
